Role of inflammation following an acute myocardial infarction: design of INFINITY.
Andreas MitsisPanayiotis AvraamidesJohn LakoumentasMichaela KyriakouStefanos SokratousGeorgia KarmiotiMichail DrakomathioulakisKonstantinos C TheodoropoulosAthina NasoufidouAlexandros EvangeliouVassilios P VassilikosNikolaos FragakisAntonios ZiakasStergios TzikasGeorge KassimisPublished in: Biomarkers in medicine (2024)
After a myocardial infarction, the inflammatory response is connected to major adverse outcomes such as ischemia-reperfusion injury, adverse cardiac remodeling, infarct size and poor prognosis. INFlammatIoN amI sTudY (INFINITY) is a multicenter, prospective, observational, cohort study designed to investigate the prognostic role of the cytokines IL-6, IL-10, IL-18 and IL-17 and the adipokines leptin, apelin and chemerin in patients with acute coronary syndrome. The study will test if these inflammatory biomarkers reflect different clinical manifestations of coronary artery disease and have a prognostic role in a 6-month follow-up period. This study represents an opportunity to investigate further the prognostic role of a selected combination of proinflammatory and anti-inflammatory biomarkers in the prognosis and risk stratification of acute coronary syndrome patients.
Keyphrases
- acute myocardial infarction
- poor prognosis
- acute coronary syndrome
- coronary artery disease
- oxidative stress
- inflammatory response
- left ventricular
- percutaneous coronary intervention
- ischemia reperfusion injury
- heart failure
- long non coding rna
- end stage renal disease
- type diabetes
- newly diagnosed
- clinical trial
- chronic kidney disease
- toll like receptor
- coronary artery bypass grafting
- prognostic factors
- peritoneal dialysis